tiprankstipranks
Trending News
More News >
Cingulate Inc (CING)
NASDAQ:CING
US Market
Advertisement

Cingulate Inc (CING) AI Stock Analysis

Compare
338 Followers

Top Page

CING

Cingulate Inc

(NASDAQ:CING)

Rating:47Neutral
Price Target:
Cingulate Inc.'s overall stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, such as securing a grant and progress towards FDA approval, provide a positive outlook. The technical analysis shows neutral momentum, but valuation remains a concern due to financial losses and lack of dividends.
Positive Factors
Market Potential
Considering the ongoing stimulant shortages, especially for generic stimulant products, and that CTx-1301 only requires one dose, daily, the commercial opportunity for Cingulate is attractive.
Product Efficacy
Cingulate's CTx-1301 demonstrated potential best-in-class onset and duration for ADHD, making it a competitive differentiator amidst ongoing stimulant shortages.
Regulatory Progress
FDA suggests Cingulate may file NDA for CTx-1301 with existing data, indicating sufficient data is already available for submission.
Negative Factors
Financial Performance
Cingulate reported a net loss of $6.1M for the fourth quarter and $15.5M for the year, which could be a concern for investors.
Operating Expenses
Operating expenses in the fourth quarter were significantly higher than expected, potentially affecting financial performance.
Statistical Significance
Despite achieving clinical meaningfulness, the Phase 3 study did not achieve statistical significance as it was not powered for this objective.

Cingulate Inc (CING) vs. SPDR S&P 500 ETF (SPY)

Cingulate Inc Business Overview & Revenue Model

Company DescriptionCingulate Inc. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of innovative therapies for the treatment of central nervous system disorders. Operating primarily in the healthcare and pharmaceutical sectors, the company is dedicated to addressing unmet medical needs through its portfolio of proprietary drug candidates, with a particular emphasis on attention deficit/hyperactivity disorder (ADHD) and anxiety disorders.
How the Company Makes MoneyCingulate Inc. generates revenue through the research, development, and eventual commercialization of its proprietary drug formulations. The company focuses on advancing its product candidates through clinical trials and obtaining regulatory approvals, which would enable them to market these drugs to healthcare providers and patients. Revenue streams are expected to include sales of approved medications, licensing agreements, and potential partnerships with other pharmaceutical companies. Additionally, Cingulate may engage in collaborative research arrangements that provide funding and milestone payments, contributing to its financial inflows.

Cingulate Inc Financial Statement Overview

Summary
Cingulate Inc. faces significant financial challenges with no revenue, persistent losses, and negative cash flows. The lack of debt is a positive aspect, but zero equity and dependency on external funding highlight financial instability.
Income Statement
2
Very Negative
Cingulate Inc. has consistently reported zero revenue across the years, indicating no sales or commercialization activities. The company is experiencing significant losses, with negative EBIT and Net Income frequently worsening year over year. There is no revenue growth, and both EBIT and EBITDA margins are negative, highlighting operational inefficiencies and financial distress.
Balance Sheet
5
Very Negative
The company has no debt as of the latest report, which is a positive aspect. However, the stockholders' equity is zero, indicating a lack of financial cushion. Historical data shows negative equity in some years, highlighting financial instability. The absence of liabilities may be misleading due to the lack of assets compared to the company’s size and industry norms.
Cash Flow
10
Very Negative
Operating cash flow is consistently negative, reflecting ongoing cash burn without revenue generation. The free cash flow is also negative, indicating that the company is not generating sufficient cash to cover its operational needs. There is no growth in free cash flow, and the heavy reliance on financing cash flow suggests dependency on external funding to sustain operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue0.000.000.000.000.00
Gross Profit0.00-582.92K-621.99K-808.44K-842.35K
EBITDA-15.64M-22.95M-17.05M-19.87M-6.29M
Net Income-15.55M-23.53M-17.85M-20.74M-7.28M
Balance Sheet
Total Assets14.86M3.49M11.41M22.89M5.79M
Cash, Cash Equivalents and Short-Term Investments12.21M52.42K5.36M16.49M1.20M
Total Debt5.10M3.14M5.53M881.13K2.05M
Total Liabilities7.41M10.36M7.52M2.04M4.50M
Stockholders Equity7.46M-6.87M-69.41M20.84M1.29M
Cash Flow
Free Cash Flow-18.66M-16.04M-11.25M-7.21M
Operating Cash Flow-18.45M-15.03M-15.88M-10.43M-6.81M
Investing Cash Flow-211.80K-224.00K-152.65K-814.74K-384.17K
Financing Cash Flow30.82M9.96M4.90M26.54M7.97M

Cingulate Inc Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.37
Price Trends
50DMA
4.32
Positive
100DMA
4.16
Positive
200DMA
4.31
Positive
Market Momentum
MACD
0.34
Negative
RSI
64.67
Neutral
STOCH
73.51
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CING, the sentiment is Positive. The current price of 5.37 is above the 20-day moving average (MA) of 4.67, above the 50-day MA of 4.32, and above the 200-day MA of 4.31, indicating a bullish trend. The MACD of 0.34 indicates Negative momentum. The RSI at 64.67 is Neutral, neither overbought nor oversold. The STOCH value of 73.51 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CING.

Cingulate Inc Risk Analysis

Cingulate Inc disclosed 77 risk factors in its most recent earnings report. Cingulate Inc reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Cingulate Inc Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
47
Neutral
$27.64M-358.06%95.52%
46
Neutral
$16.48M-362.79%32.45%39.31%
44
Neutral
$11.47M-68.18%45.24%
37
Underperform
$11.87M-105.79%-82.54%-12.53%
36
Underperform
$14.08M-63.94%22.63%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CING
Cingulate Inc
5.37
1.13
26.65%
CARM
Carisma Therapeutics
0.39
-0.79
-66.95%
HOOK
Hookipa Pharma
0.91
-5.24
-85.20%
NXTC
NextCure
5.26
-14.42
-73.27%
PHGE
BiomX
0.44
-1.80
-80.36%

Cingulate Inc Corporate Events

Product-Related AnnouncementsPrivate Placements and Financing
Cingulate Inc Secures $3M Grant for Anxiety Drug
Positive
Apr 9, 2025

On April 8, 2025, Cingulate Inc. entered into a Grant Agreement with a private foundation to receive a $3 million grant for the development of CTx-2103, a once-daily formulation of buspirone for anxiety treatment. This funding, distributed in three $1 million payments, will accelerate Cingulate’s pipeline and validate its PTR technology, potentially reducing reliance on benzodiazepines and addressing a significant market need in the $5.5 billion U.S. anxiety market.

Spark’s Take on CING Stock

According to Spark, TipRanks’ AI Analyst, CING is a Neutral.

Cingulate Inc.’s stock score is primarily impacted by its poor financial performance, with persistent losses and negative cash flows. However, recent corporate developments, including progress towards FDA approval for CTx-1301, provide a significant positive outlook. Technical indicators show neutral market momentum, but valuation remains a concern due to financial losses and lack of dividends.

To see Spark’s full report on CING stock, click here.

Product-Related AnnouncementsRegulatory Filings and Compliance
Cingulate Inc. Advances Towards FDA Approval for CTx-1301
Positive
Mar 4, 2025

On March 4, 2025, Cingulate Inc. announced the safety results from its final Phase 3 trials for CTx-1301, a novel, once-daily stimulant medication for ADHD, which showed no serious adverse events and consistent safety profiles. The results, submitted to the FDA ahead of an April 2 meeting, mark a significant step towards filing for FDA approval mid-2025, potentially positioning Cingulate as a leader in ADHD treatment with a product that addresses unmet needs in the market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 20, 2025